To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.
A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.
The evidence behind many guidance statements is limited in quality.
These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.Le texte complet de cet article est disponible en PDF.
Key words : biologics, COVID-19, psoriasis, psoriatic arthritis, SARS-CoV-2
Abbreviations used : CDC, COVID-19, NPF, SARS COV-2, TF, TNF
| Funding sources: None.
| Conflicts of interest: Dr Anesi has pending fees from UpToDate for authoring COVID-19 clinical reference material, and research time is supported by the Agency for Healthcare Research and Quality K12HS026372. Dr Armstrong has served as a research investigator and/or scientific advisor to LEO Pharma, AbbVie, UCB, Janssen, Eli Lilly and Company, Novartis, Ortho Dermatologics, Sun, Dermavant, BMS, Sanofi, Regeneron, Dermira, and Modmed. Dr Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie. Authors Bell, Gondo, Heydon, Koons, and Smith are employees of the National Psoriasis Foundation. Dr Calabrese is a speaker for Sanofi-Regeneron and a consultant for AbbVie. Dr Feldman received research, speaking, and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, LEO Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. Dr Feldman also consults for others through Guidepoint Global, Gerson Lehrman, and other consulting organizations, is the founder and majority owner of www.DrScore.com, and is also a founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis, Sanofi, Celgene, Ortho Dermatologics, and Pfizer, has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics, is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Gladman is a consultant for AbbVie, Amgen, BMS, Galapagos, Gilead, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB, and receives grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Dr Kircik has served as an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol-Myers Squibb, Boehringer Ingelheim, Cellceutix, Celgene, Coherus, Dermavant, Dermira, Eli Lilly and Company, LEO Pharma, MC2, Maruho, Novartis, Ortho Dermatologics, Pfizer, Dr. Reddy's Laboratories, Sun Pharma, UCB, Taro, and Xenoport. Dr Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB, and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis Inc, Avotres Therapeutics, BirchBioMed Inc, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica. Dr Martin is a consultant for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB, and is a scientific advisor for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB. Dr Merola is a consultant and/or investigator for Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Sun Pharma, Pfizer, and EMD Sorono. Dr Ritchlin reports personal fees from AbbVie, Amgen, Janssen, Novartis, UCB, and Boerhinger Ingelheim, and grants from Amgen, UCB, and AbbVie outside the submitted work. Dr Schwartzman is a speaker for AbbVie, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, and UCB, owns stock in Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer, is a consultant for AbbVie, Myriad, Janssen, Gilead, Eli Lilly and Company, Novartis, and UCB, is a scientific advisory board member for Myriad, and is a board member of the National Psoriasis Foundation. Dr Scher is a consultant for UCB, Janssen, AbbVie, Pfizer, Novastis, and Sanofi. Dr Syed is supported by a grant from Pfizer. Dr Van Voorhees has been an investigator for Celgene, Eli Lilly and Company, and AbbVie, and has been an advisor/consultant for AbbVie, Allergan, AstraZeneca, Celgene, Dermira, Merck, Novartis, Pfizer, UCB, and Valeant. Drs Weinstein, Ellebrecht, Ocon, Fenner, Treat, Dommasch, and Lo Re have no conflicts of interest to disclose.
| IRB approval status: Not applicable.
| Reprints not available from the authors.